Matthew Walsh Paid for $321880 Worth of Allergan plc (AGN) Stock; Sunshine Bancorp (SBCP) Sentiment Is 1.04

February 22, 2018 - By Dolores Ford

A calculated and judicious act was made by the EVP – Chief Financial Officer of Allergan Plc, Mr. Matthew Walsh, yesterday, when he acquired 2,000 shares, totalling $321,880 US Dollars, at an average $160.9 for each share. For complete details of this deal please access the Security Exchange Commission’s Form 4 available for review here. Right now, Matthew Walsh owns a total of 24,416 shares or 0.01% of Allergan Plc’s total market cap.

Sunshine Bancorp, Inc. operates as the holding firm for Sunshine Bank that provides financial services to individuals, families, and businesses. The company has market cap of $184.12 million. The firm accepts various deposit accounts, such as interest-bearing and noninterest-bearing demand and checking, money market, and savings accounts; time deposits; and certificates of deposit. It has a 38.95 P/E ratio. The Company’s loan products include commercial real estate and multi-family loans; one-to-four family residential real estate loans; commercial business loans, such as term loans, lines of credit, agricultural production, equipment financing, and revolving lines of credit; construction and land loans; home equity loans comprising revolving lines of credit, and term or second mortgage loans; and consumer loans.

The stock decreased 0.74% or $0.17 during the last trading session, reaching $22.94. About 148,273 shares traded or 373.08% up from the average. Sunshine Bancorp, Inc. (SBCP) has risen 64.09% since February 22, 2017 and is uptrending. It has outperformed by 47.39% the S&P500.

Seidman Lawrence B holds 2.63% of its portfolio in Sunshine Bancorp, Inc. for 160,251 shares. Mendon Capital Advisors Corp owns 361,070 shares or 0.7% of their US portfolio. Moreover, Knott David M has 0.28% invested in the company for 27,800 shares. The Illinois-based Banc Funds Co Llc has invested 0.22% in the stock. Gabelli & Co Investment Advisers Inc., a New York-based fund reported 75,000 shares.

Among 27 analysts covering Allergan Inc. (NYSE:AGN), 19 have Buy rating, 0 Sell and 8 Hold. Therefore 70% are positive. Allergan Inc. has $400 highest and $171.0 lowest target. $260.27’s average target is 63.28% above currents $159.4 stock price. Allergan Inc. had 109 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Raymond James on Tuesday, September 29. The rating was downgraded by Mizuho to “Neutral” on Wednesday, April 6. Canaccord Genuity maintained it with “Buy” rating and $396 target in Sunday, August 9 report. The firm has “Buy” rating by Mizuho given on Friday, August 19. As per Thursday, July 20, the company rating was maintained by Credit Suisse. The firm has “Outperform” rating by Leerink Swann given on Monday, November 27. The stock of Allergan plc (NYSE:AGN) has “Neutral” rating given on Thursday, April 7 by Susquehanna. The rating was maintained by Deutsche Bank on Thursday, April 7 with “Buy”. The firm has “Buy” rating by RBC Capital Markets given on Friday, July 14. As per Thursday, January 4, the company rating was maintained by RBC Capital Markets.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $52.65 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Analysts await Allergan plc (NYSE:AGN) to report earnings on May, 8. They expect $3.35 EPS, 0.00% or $0.00 from last year’s $3.35 per share. AGN’s profit will be $1.11 billion for 11.90 P/E if the $3.35 EPS becomes a reality. After $4.86 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -31.07% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: